Quantcast
Last updated on April 17, 2014 at 9:58 EDT

Latest Pyrazines Stories

2009-05-30 15:17:00

Promising Anti-cancer Activity Observed in Relapsed Patients ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc. today reported on clinical advances for its carfilzomib solid tumor program in an oral presentation at the 2009 Annual Meeting of the American Society of Oncology (ASCO) in Orlando, Florida. Data from a Phase 1b study and an ongoing Phase 2 clinical trial of carfilzomib in relapsed patients with advanced solid tumors demonstrate promising...

2009-05-15 07:30:00

Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc. today announced that data from clinical trials of carfilzomib in multiple myeloma and advanced solid tumors will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 - June 2, 2009 in Orlando, Florida. Carfilzomib is the first in...

2009-03-03 09:02:53

People with a likely history of depression who take varenicline (Chantix®) do not report more severe mood symptoms, medication side effects, or less success quitting smoking compared to people with no history of depression taking this drug.  The findings by Group Health, Free & Clear, and SRI International researchers are reported in a Journal of General Internal Medicine article published online (www.springerlink.com/content/77207452k3822r3v/). The National Cancer...

2009-02-26 07:29:00

New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated clinical results from an ongoing Phase 1/2 study of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. The data, which was presented earlier today in a poster featured at...

2009-02-11 14:10:00

EUSAPharma (formerly Cytogen) Posts Positive Phase I Report from Trial of Quadramet in Combination with Velcade for the Treatment of Relapsed or Refractory Multiple Myeloma. LOS ANGELES, Feb. 11 /PRNewswire/ -- Quadramet (153 Samarium-lexidronam) is a radioactive medication that targets the bone, specifically bone cancer, and is used to treat pain caused by cancer that has metastasized or spread to the bone. Velcade (bortezomib) is approved for the treatment of multiple myeloma alone and in...

2009-02-03 14:30:00

WASHINGTON, Feb. 3 /PRNewswire-USNewswire/ -- Green tea products have become regarded as a valuable health supplement, as studies have shown evidence of its benefit against a variety of diseases, including cancer. However, a new study suggests that some components of green tea may counteract the anticancer effects of one cancer therapy, bortezomib (Velcade(R)), and may be contraindicated for patients taking this medicine to ensure its maximum therapeutic benefit. This study is being...

2009-01-16 12:32:00

ANN ARBOR, Mich., Jan. 16 /PRNewswire/ -- Use of prescription sleep aids nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a study released today by the Healthcare business of Thomson Reuters. During the study period, the average length of time sleep aids were used by adults under age 45 increased more than 40 percent -- rising from 64 days in 1998 to 93 days in 2006. "Insomnia, a condition traditionally associated with older adults, appears to be...

fa1ba12e98af16b03725744acd26cf5d1
2009-01-16 06:55:00

Need the help of a pill to catch some zzz's? According to a new study you're not alone; the use of prescription sleep aids nearly tripled among young adults between 1998 and 2006."Insomnia, a condition traditionally associated with older adults, appears to be causing larger numbers of young adults to turn to prescription sleep aids, and to depend on them for longer periods of time," said William Marder, senior vice president and general manager for the healthcare business of Thomson Reuters,...

2008-12-09 09:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of specific proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Sundar Jagannath, M.D., Chief of the...

2008-12-08 16:46:00

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results from two large, multi-center, randomized Phase III clinical trials of VELCADE based combinations for the induction treatment of transplant-eligible patients with previously untreated multiple myeloma (MM). Prolonged progression-free survival (PFS) was observed in one study comparing VELCADE and dexamethasone (VcD) with vincristine, adriamycin and dexamethasone (VAD), as well as in...